諾輝健康(6606.HK)聯手中郵電商，防癌篩查下沉鄉鎮最後一公里
8月11日，諾輝健康(6606.HK)與中國郵政集團旗下中郵電子商務有限公司(以下簡稱“中郵電商”)簽署合作協議，雙方將攜手推動噗噗管®和常衞清®的推廣和在鄉鎮地區的下沉與普及，助力腸道健康防癌篩查“最後一公里”。
中郵電商總經理李唐與諾輝健康執行董事兼CEO朱葉青
此次合作，中郵電商將上線諾輝健康旗下國內首個居家自測便潛血檢測產品噗噗管®和“中國癌症早篩第一證”產品常衞清®，向中國郵政系統內線上線下的企業和個人用户全面推廣，科普腸道健康的價值和科學的腸癌風險預防常識，在醫療資源相對匱乏、交通成本較高的鄉鎮地區，通過居家篩查產品提升居民防癌自測的依從性，修築起守衞腸道健康的第一道屏障。
近年來，中國郵政積極佈局醫療健康業務，依託31省(區、市)建制村直接通郵率達100%的獨家優勢，送藥下鄉，有效解決鄉鎮居民獲取醫療資源不便的難點。2019年，中國郵政在寧夏試點開設第一家中郵大藥房，2020年7月，北京首家以郵政網點為經營主體的便民藥店在房山區青龍湖郵政所正式開業，目前已覆蓋多個省市。
“40多年前，浙江大學腫瘤研究所鄭樹教授在浙江省嘉善海寧地區完成了中國首次腸癌篩查，此後持續跟蹤了幾十年，大規模人羣篩查顯著降低了當地腸癌的發病率和死亡率。”諾輝健康執行董事兼CEO朱葉青講到，“居家篩查新技術研發、 臨牀驗證和應用始終得到了鄭樹教授和她的團隊親身參與和指導，諾輝健康的初心 是做用户好用願意用的篩查產品。此次合作，我們非常高興與‘國家隊’聯手，把防癌篩查的理念和便捷送達廣大鄉鎮的每一個角落，真正做到防癌篩查關口前移，重心下沉。”
中郵電子商務有限公司總經理李唐表示，“中國5億人口生活在鄉村，而中國郵政的資源和基礎設施在農村，絕大多數的網點和客户在農村，‘人民郵政為人民’是中國郵政不變的初心使命。諾輝健康旗下癌症篩查產品與郵政致力於打造的惠農項目十分契合，本次合作希望通過觸達更多的郵政客户，推動大眾提高腸癌早發現早診療的意識，使廣大基層百姓不必行遠便可收穫一份放心。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
